Evidence map›Paper›PMID 33655128›Full record

ArticleSpartan medical research journal2017

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem.

John M Cannon, Richard W Douce, Erin R Grubbs, Christopher B Wills, Asam Khan, Elizabeth M Schmidt, Michael S Wang

Open access · hybridAbstract read
PubMed Full text at PMC
In one paragraph

Article in Spartan medical research journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

John M CannonLakeland Health Department of Pharmacy, Clinical Pharmacist, St. Joseph, MI.
Richard W DouceLakeland Health Department of Medicine, Core Faculty, St. Joseph, MI, Lakeland Health Internal Medicine Resident, PGY-3 Resident, St. Joseph, MI.
Erin R GrubbsLakeland Health Department of Pharmacy, Clinical Pharmacist, St. Joseph, MI.
Christopher B WillsLakeland Health Internal Medicine Resident, PGY-3 Resident, St. Joseph, MI.
Asam KhanLakeland Health Internal Medicine Resident, PGY-3 Resident, St. Joseph, MI.
Elizabeth M SchmidtLakeland Health Internal Medicine Resident, PGY-3 Resident, St. Joseph, MI.
Michael S WangLakeland Health Internal Medicine, Program Director, St. Joseph, MI.
Lakeland Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextEmpiric antibiotics are often required in hospitalized patients with serious infections who may be septic and at risk for drug resistant organisms. The purpose of this study was to evaluate the observed incidence of acute kidney injury (AKI) in a sample of adult patients receiving either piperacillin-tazobactam and vancomycin or meropenemvancomycin for at least 72 hours.

methodsSingle-center, retrospective matched cohort at a 200-bed Regional Community Medical Center. Adult patients were included in the sample if they were without preexisting renal dysfunction and admitted over an 18-month time period to receive either the combination of piperacillin-tazobactam and vancomycin or meropenem-vancomycin. Sample patients were evaluated for AKI. This condition was defined by the authors as an increase in serum creatinine of 0.5mg/ml or an increase of 50% above baseline during the duration of antibiotic treatment.

resultsA total of 266 patients receiving either combination of antibiotics were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin-tazobactam and vancomycin group (n = 74/292, 25%) compared with the meropenem-vancomycin group (n=8/74, 9.5%, p=0.008).

conclusionsThe results of this study suggest that the combination of piperacillin-tazobactam and vancomycin is associated with an increased incidence of AKI. Higher vancomycin trough concentrations were associated with increased risk for development of AKI.

Indexed as

meropenemnephrotoxicitypiperacillin-tazobactamvancomycin

Identifiers

PMID33655128
PMCPMC7746064
OpenAlexW3132915353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.